Fraiser Kansteiner

After the recent FDA approval for the promising schizophrenia drug Cobenfy (xanomeline and trospium chloride), Bristol Myers Squibb and its partners are moving fast to expand the global reach of the novel antipsychotic.

Despite a somewhat ambling launch, Biogen’s Eisai-partnered Alzheimer’s disease drug Leqembi continues to grow.

Biopharma production efforts are set to receive a big boost in the U.K. thanks to a new budget rolled out by the Labour Party following this summer's general election.

Some two years after the European Commission accused Teva of meddling with the competition for its former multiple sclerosis blockbuster Copaxone, the other shoe has finally dropped.

Less than a month after the FDA removed Eli Lilly's tirzepatide from its shortage list, the agency has done the same for Novo Nordisk's rival GLP-1

A trio of antitrust complaints stretching back to 2016 have yielded a payoff, with generic drugmakers Heritage Pharmaceuticals and Apotex now on the hook to lay out a combined $49.1 million in settlement charges.

With a positive readout for metabolic dysfunction-associated steatohepatitis (MASH) now in the bag, Novo Nordisk is gearing up to pursue yet another indication for its star GLP-1 medicine semaglutide.

Despite winning an alopecia areata approval for its drug Leqselvi in July, Sun Pharma will have to wait a while longer to launch its JAK inhibitor competitor to Eli Lilly and Incyte’s Olumiant and

After a protracted rough patch—which has included layoffs, partnership terminations and lawsuits—San Francisco's Nektar Therapeutics is extending its cash runway with the sale of one of its two main facilities.

As the U.K. works to pump fresh cash into the local biopharma scene, London's Accord Healthcare is capitalizing on the government's renewed willingness to chip in.